Skip to main content

Table 1 Description of patients and tumors

From: Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis

  Recurrence No recurrence Analyzed cohort Excluded
N 124 71 195 17
Age mean ± SD (years) 44.8 (14.4) 51.1 (13.4) 47.1 (14.3%) 43.3 (16.3)
Sex     
 F 50 (40.3%) 34 (47.9%) 84 (43.1%) 8 (47.1%)
 M 74 (59.7%) 37 (52.1%) 111 (56.9%) 9 (52.9%)
Tumor type     
 Gonadotroph 33 (26.6%) 23 (32.4%) 56 (28.7%) 2 (11.7%)
 Immunonegative 5 (4.0%) 6 (8.5%) 11 (5.6%) 1 (5.9%)
 Somatotroph 40 (32.2%) 16 (22.5%) 56 (28.7%) 13 (76.5%)
 GNASwt 31 9 40 /
 GNAS mutation 7 6 13 /
 GNAS Not available 2 1 3 /
 Lactotroph 28 (22.6%) 11 (15.5%) 39 (20.0%) 0 (0%)
 Corticotroph 18 (14.6%) 15 (21.1%) 33 (17.0%) 1 (5.9%)
 USP8wt 12 10 22 /
 USP8 mutation 3 2 5 /
 USP8 Not available 3 3 6 /
Grade     
 1a 26 (21.0%) 36 (50.7%) 62 (31.9%) 2 (13.3%)
 1b 4 (3.2%) 5 (7.0%) 9 (4.6%) 1 (6.7%)
 2a 64 (51.6%) 25 (35.3%) 89 (45.6%) 7 (46.7%)
 2b 30 (24.2%) 5 (7.0%) 35 (17.9%) 5 (33.3%)
Size     
 Microadenomas 4 (3.2%) 9 (12.7%) 13 (6.7%) 2 (11.8%)
 Macroadenomas 111 (89.6%) 62 (87.3%) 173 (88.7%) 15 (88.2%)
 Giant adenomas 8 (6.4%) 0 8 (4.1%) 0
 Not available 1 (0.8%) 0 1 (0.5%) 0